Rofecoxib for osteoarthritis

Garner, Sarah; Fidan, Dogan; Frankish, Ruth R; Maxwell, Lara

doi:10.1002/14651858.cd005115

Cited by 31 publications

(18 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, state-of-the-art weight loss policy among obesity specialists is that the overweight individual initiates a 10% reduction in body weight, which reduces multiple risk factors. 4 65 With these guidelines, the effect of the weight loss may be achieved within a few months, resulting in a clinical ES larger than most non-operative treatments systematically reviewed, applying meta-analyses, [66][67][68][69] and at least comparable to the possible effect of walking. 70 In the present meta-analysis, it is obvious that the strategies applied in the individual RCTs combine great diversity in both magnitude and intensity of the (weight-reducing) dietary strategies.…”

Section: Discussionmentioning

confidence: 99%

Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis

Christensen

Bartels

Astrup

et al. 2006

Annals of the Rheumatic Diseases

550

378

View full text Add to dashboard Cite

This review aims to assess by meta-analysis of randomised controlled trials (RCTs) changes in pain and function when overweight patients with knee osteoarthritis (OA) achieve a weight loss. Systematic searches were performed and reference lists from the retrieved trials were searched. RCTs were enclosed in the systematic review if they explicitly stated diagnosis of knee OA and reported a weight change as the only difference in intervention from the control group. Outcome Measures for Arthritis Clinical Trials III outcome variables were considered for analysis. Effect size (ES) was calculated using RevMan, and meta-regression analyses were performed using weighted estimates from the random effects analyses. Among 35 potential trials identified, four RCTs including five intervention/ control groups met our inclusion criteria and provided data from 454 patients. Pooled ES for pain and physical disability were 0.20 (95% CI 0 to 0.39) and 0.23 (0.04 to 0.42) at a weight reduction of 6.1 kg (4.7 to 7.6 kg). Meta-regression analysis showed that disability could be significantly improved when weight was reduced over 5.1%, or at the rate of .0.24% reduction per week. Clinical efficacy on pain reduction was present, although not predictable after weight loss. Metaregression analysis indicated that physical disability of patients with knee OA and overweight diminished after a moderate weight reduction regime. The analysis supported that a weight loss of .5% should be achieved within a 20-week period-that is, 0.25% per week. Being overweight is an important factor in osteoarthritis (OA), and obese subjects are at high risk of developing OA in the knee.1 The average body weight of the increasing number of elderly people has steadily risen in recent years. 2The obesity problem appears across multiple age groups, 3 and there is reason to believe that the obesity-related knee OA will increase in both numbers and severity.4 5 Obesity must be taken seriously in any discussion concerning health issues, 6 including that of the bone and joints.7 Current European evidence-based recommendations for the management of knee OA, devised by the European League Against Rheumatism, include weight loss as a sensible option in overweight patients with knee OA. However, this recommendation is primarily supported by expert opinion 8 ; meta-analysis of randomised controlled trials (RCTs; ie, category 1a evidence) is yet to be undertaken.The objective of this systematic review and meta-analysis was to assess and quantify whether the clinical benefits (changes in pain and functional disability) 9 are evident in patients with knee OA after weight loss. Applying the rules of evidence-based medicine, 10 11 with focus on quality (ie, magnitude and intensity) of the intervention, 12 we aimed to meta-analyse 13 and present doseresponse efficacy estimates of weight loss in obese patients with knee OA. METHODSRetrieval of published studies A systematic literature search was carried out to identify and locate all controlled and preferably randomised trial...

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis

Christensen

Bartels

Astrup

et al. 2006

Annals of the Rheumatic Diseases

550

378

View full text Add to dashboard Cite

show abstract

“…This observation was probably attributable to the cardiovascular (CV) safety concerns of coxibs, leading to rofecoxib withdrawal in September 2004. 11 In April 2005, valdecoxib was withdrawn for concerns on CV safety and serious skin reactions and lumiracoxib in December 2007 for reasons of hepatotoxicity. 12,13 Although the effect of rofecoxib withdrawal on switches in classes of NSAID prescriptions has been studied before, 14,15 the impact on the accuracy of the prescription of preventive strategies remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal ‐ a 617 400‐patient study

Valkhoff

Soest²,

Masclee

et al. 2012

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…When treating low back pain, the proprietary S. daphnoides extract Assalix was not inferior to 12.5 mg rofecoxib, 3 which is a very low dose (rofecoxib doses up to 50 mg have been used for the treatment of osteoarthritis) 4 . It may well be that higher S. daphnoides extract doses may compete with 100 mg diclofenac in the treatment of osteoarthritic pain, if not, different ingredient composition of the investigated Salix daphnoides bark extract or bias are responsible for its ineffectiveness.…”

Section: Commentarymentioning

confidence: 95%

Salix daphnoides (willow bark) extract and osteoarthritic and rheumatoid arthritic pain

2005

Focus on Alt & Comp Therapy

View full text Add to dashboard Cite

Rofecoxib for osteoarthritis

Cited by 31 publications

References 73 publications

Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis

Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis

Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal ‐ a 617 400‐patient study

Salix daphnoides (willow bark) extract and osteoarthritic and rheumatoid arthritic pain

Contact Info

Product

Resources

About